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Mortality at 30 days and 1 year was 11.8% and 22.7%, respectively. At one year follow-
up, all but one patient was NYHA class 1 or 2 and the mean gradient across the aortic
valve remained stable (14 ± 5 mmHg).
Conclusion: This multicenter study shows that THV-in-THV implantation is feasible
and results in satisfactory short and mid-term outcomes.
TCT-127
Low pre-procedural trans-aortic gradient predicts adverse clinical outcome
after transcatheter aortic valve implantation
Nicolas Amabile, Ramzi Ramadan, Said Ghostine, Alexandre Azmoun, François
Raoux, Ngoc-Tram To, Xavier Troussier, Yacine Haddouche, Remi Nottin,
Christophe Caussin
Interventional Cardiology, Centre Marie Lannelongue, Le Plessis Robinson, France
Background: Despite growing interest in transcatheter aortic valve implantation
(TAVI) as an alternative to surgical aortic valve replacement for select patients with
severe aortic stenosis, relatively little is known about the predictors of adverse
outcomes following TAVI.
Methods: We studied 126 consecutive patients (mean age 84±5 years; 59% women;
Euroscore: 21.3±11) with symptomatic severe aortic stenosis (aortic valve area<0.6
cm2/m2 and NYHA class≥III) who underwent TAVI at our institution between
November 2008 and May 2011 using transfemoral Edwards-Sapien© (66%),
transapical Edwards-Sapien© (23%) and transfemoral Medtronic Corevalve© (11%)
devices. The primary end-point was the occurrence of any cardiovascular death (fatal
stroke, MI, heart failure and/or sudden cardiac death). We also recorded the incidence
of major adverse cardiovascular events (MACE), that combined cardiovascular death+
stroke+ myocardial infarction+ acute heart failure.
Results: The acute procedural success rate was 98%; at 1 year, the cumulative
incidence of MACE and cardiovascular death was 31.1% and 9 %, respectively. In
multivariable analyses adjusting for clinical and echocardiographic risk factors
(including left ventricle ejection fraction), presence of a baseline transvalvular gradient
<40 mmHg was a significant predictor of 30-day MACE in the total sample (OR=4.5,
95% CI 1.6-12.4; P=0.004) as well as in patients with an ejection fraction ≥50%
(OR=12.5, 95% CI 3.4-46.2; P<0.001). In multivariable analyses, low transvalvular
gradient was also associated with increased hazards for MACE (HR=3.2, 95% CI 1.6-
6.4; P<0.001) and cardiovascular death (HR=3.9 95% CI 1.1-13.9; P=0.03) within 1
year following TAVI
Conclusion: Presence of a low transvalvular gradient (<40 mmHg) prior to TAVI was
associated with a greater risk of major adverse events, including cardiovascular death,
up to 1 year following the procedure. Pre-procedural transvalvular gradient could be
used to identify patients at a high risk for adverse outcomes following TAVI.
TCT-128
Transaortic Transcatheter Aortic Valve Implantation Using the Sapiens Valve
for Patients with no Optional Artery Access. A New Promising Approach
Kentaro Hayashida, Mauro Romano, Thierry Lefevre, Thomas Hovasse, Erik
Bouvier, Daniel Le Houerou, François Decailliot, Philippe Garot, Bernard
Chevalier, Marie-Claude Morice, Bertrand Cormier
Institut Cardiovasculaire Paris Sud, Massy, France
Background: Access for transcatheter aortic valve implantation (TAVI) in patients
with no optional peripheral artery access still remains a serious issue, since transapical
approach is frequently associated with myocardial damage and pleural effusion.
Recently, Transaortic (TAo) approach has been developed to address these problems.
The purpose of this study was to evaluate the efficacy and safety of TAo approach in
TAVI using the Edwards Sapien valve.
Methods: Among 365 patients included in our prospective TAVI database (October
2006 to June 2011), TAo-TAVI was performed in 25 consecutive patients excluded
from femoral or subclavian access since january 2011. We evaluated the clinical
outcomes according to the VARC definitions. The access was carefully selected
according to CT-scan assessment of ascending aorta. Through an upper
ministernotomy, the aorta was prepared for cannulation and punctured. After retrograde
crossing of the aortic valve, the Ascendra sheath was inserted to deploy the valve after
predilatation.
Results: Patients were 84.9±4.2 (76-93) years old and EuroSCORE 17.1±7.9%. The
23 mm valve was used in 5 cases, 26mm in 15 and 29mm in 5. In 4 patients, complete
off pump revascularization (2-4 grafts) was achieved in the same session before TAVI.
Device success was achieved in all cases. Post-procedural aortic regurgitation ≥2/4
was observed in 1 case (4%). Transfusion ≥4units was required in 1 patient (10%) who
had annulus rupture successfully corrected. There were no access site complications,
no cases of valve migration or conversion to open-heart surgery. Intensive care unit
and total hospital stay were 3.1±2.1 and 19.0±6.8 days, respectively. Mortality and
combined safety endpoint at 30-day was noted in 0 and 10%, respectively.
Conclusion: Transaortic approach for Sapiens XT valve implantation can be performed
with a low complication rate and excellent outcome. This approach may be a promising
alternative to the conventional transapical approach.
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Outcome of Conservative Management in Patients with Aortic Valve Stenosis
Ineligible for Transcatheter Treatment
Massimo Napodano, Ermela Yzeiraj, Valeria Gasparetto, Chiara Fraccaro,
Giuseppe Tarantini, Paolo Buja, Gianclaudio Falasco, Roberto Bianco, Gino
Gerosa, Giambattista Isabella, Sabino Iliceto
Dpt. of Cardiac Thoracic and Vascular Sciences. University of Padova, Padova,
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Background: Transcatheter Aortic Valve Implantation (TAVI) favourably compared
to conservative management in inoperable patients and to surgery in high-risk patients
affected by aortic stenosis. However, the outcome of high-risk and inoperable patients
resulting ineligible for TAVI has not been yet investigated. We prospectively evaluated
clinical outcome of patients affected by aortic valve stenosis ineligible for TAVI.
Methods: All high surgical risk patients referred to our cardiovascular department for
severe aortic stenosis requiring valve replacement were included in a prospective
single-centre registry. High surgical risk was defined by the presence of: 1.age ≥ 75
with a logistic EuroSCORE ≥ 15%; or 2.age > 65 plus one or more inoperable criteria
such as porcelain aorta, previous open chest surgery, neurological dysfunction, severe
chronic obstructive pulmonary disease (FEV1 < 1L), liver cirrhosis (Child ≥B), severe
chronic kidney disease, stroke, severe connective tissue disease or hostile thorax.
Eligibility criteria for TAVI were based on clinical and anatomic characteristics
compatible with the current devices: Medtronic CoreValve III generation and Edwards
Sapien/Sapien XT transfemoral or transapical approach.
Results: Of 300 patients who were denied surgery, 225 (75%) resulted eligible for
TAVI and 75 (25%) did not. Causes of ineligibility for TAVI were frailty status (n=22),
severe mitral regurgitation (≥ 3+/4) (n=18), inadequate aortic annulus size (n=18),
severe left ventricular dysfunction (n=6), no-access (n=8) and hemorrhagic diathesis
(n=3). Of the 225 eligible for TAVI, 187 (83%) underwent TAVI with a 30-day
mortality of 4.2%; 18 (8%) died before intervention; 16 (7%) refused the procedure; 4
(2%) were excluded by referral physician and died. At 1-year, estimated survival was
89% in TAVI patients versus 49% in patients ineligible to TAVI. Indeed, cardiovascular
mortality was largely prevalent in TAVI ineligible patients, whereas non-cardiovascular
mortality was largely prevalent in TAVI patients.
Conclusion: Using current devices and approaches the most frequent causes for TAVI
ineligibility are not related to anatomical criteria but to clinical conditions. Patients
not eligible for TAVI have very high risk clinical features and very poor outcome.
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Background: SAVR is an invasive intervention, carrying a risk of perioperative
mortality and an alternative treatment option, transcatheter aortic valve implantation
(TAVI), has been developed. The clinical efficacy of TAVI was demonstrated in a
recently published randomized controlled trial (PARTNER). To date, however, there
is little information about the cost-effectiveness of TAVI relative to SAVR.
Methods: A 20 year Markov model was developed in Microsoft Excel® from the
perspective of the UK NHS. Treatment options included were TAVI and SAVR.
Treatment specific mortality and adverse event data were taken from the PARTNER
study (Cohort A) which was supplemented by UK specific life table information.
Resource use and cost data were drawn, where possible, on information from publicly
available national databases. Other parameters were taken from published literature.
Decrements were applied to age-specific EQ-5D population norms to generate Quality
Adjusted Life Years (QALYs). Alternative modelling approaches and data sources for
key parameters were included into the model. Extensive probabilistic and deterministic
sensitivity analyses were performed. Costs and benefits were discounted at an annual
rate of 3.5%
Results: The base case Incremental Cost-Effectiveness Ratio (ICER) was £30,538 per
QALY gained (95% Crl £21,322 to £39,287). At willingness to pay thresholds of
£30,000 per QALY, the probability that TAVI is cost-effective is 44%. Results were
not sensitive to changes in baseline survival curve, approach used to model the benefit
of TAVI, or procedure time, but sensitive to changes in procedure cost and resource
use.
Conclusion: TAVI may be a cost-effective alternative to conventional surgery at a
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threshold accepted by the United Kingdom reimbursement agency. Further examination
of the resource use and treatment pathway in this patient group will help to reduce the
uncertainty in the ICER.
TCT-131
Transfemoral Transcatheter Aortic Valve Implantation Versus Surgical Aortic
Valve Replacement in Patients Severe Aortic Stenosis
Marco Barbanti, Gian Paolo Ussia, Davide Capodanno, Carmelo Mignosa, Valeria
Cammalleri, Marilena Scarabelli, Patrizia Aruta, Anna Maria Pistritto, Sebastiano
Immè, Simona Gulino, Salvatore Bonura, Alessandra Cadoni, Maria Concetta Di
Pasqua, Claudio Bonanno, Maurizio Gentile, Stefano Cannata, Corrado Tamburino
Ferrarotto Hospital, University of Catania, Catania, Italy
Background: A number of large single-arm registries demonstrated that short and
long-term outcomes after Transcatheter Aortic Valve Implantation (TAVI) have the
potential to compare favorably with surgical aortic valve replacement (SAVR) in high-
risk patients. No prospectively randomized trials comparing transcatheter techniques
to conventional SAVR are available, and direct comparisons of TAVI and SAVR remain
sparse.We sought to evaluate early and mid-term outcomes of transfemoral TAVI in
comparison with conventional SAVR.
Methods: Consecutive patients (n=770) who underwent TAVI (n=164) and SAVR
(n=606) at two centers were included in this analysis. Primary endpoint was major
adverse cerebrovascular and cardiac events (MACCE) at 30-day and 1-year.
Results: Procedural MACCE occurred in 122 patients (15.9%), being more frequent
in patients treated with SAVR compared to those treated with TAVI (9.1% vs 17.7%;
p=0.008). After addressing potential confounders by using three methods of statistical
adjustment, SAVR was generally associated with a trend towards a higher risk of
MACCE than TAVI, with estimates of risk ranging from 1.9 to 2.5 at 30 days, 1.9 to
2.6 at 6 months and 1.5 to 1.9 at 12 months. However, this difference was consistently
significant only at 6 months (p=0.049 after adjustment with covariates; p=0.026 after
adjustment with covariates and propensity score; p=0.042 after adjustment with
propensity score alone), driven by an adjusted reduced risk of life threatening bleeding
(adjusted HR 4.12; 95% CI 1.11-15.29). No differences in the adjusted risk of death,
MI and stroke were noted between TAVI and SAVR at each time point.
Conclusion: In a large observational registry with admitted potential for selection bias
and residual confounding, TAVI appeared to be safer than SAVR at mid-term follow-
up.
TCT-132
Intracardiac Echocardiography: a New Guiding Tool for Transcatheter Aortic
Valve Replacement
Thomas Bartel, Nicolaos Bonaros, Ludwig Müller, Guy Friedrich, Corinna Velik-
Salchner, Silvana Müller
Medical University Innsbruck, Innsbruck, Austria
Background: The aim of this study was to comparatively evaluate intraprocedural
guidance of transcatheter aortic valve replacement (TAVR) by intracardiac and
transesophageal echocardiography (ICE, TEE).
Methods: Fifty high-risk patients with severe aortic stenosis scheduled for TAVR were
randomized to either ICE guidance (figure: A - longitudinal axis, B - short axis; group
1; n = 25) or TEE monitoring (group 2; n = 25).
Results: ICE allowed continuous monitoring. The need for probe repositioning during
the procedure was much lower in group 1 (0.1 ± 0.3 vs. 5.7 ± 0.7 manoeuvres; P <
.001). The transcaval ICE view provided higher coaxiality with the ascending aorta
expressed by the length of ascending aorta depicted (4.9 ± 1.2 vs. 6.1 ± 1.2 cm, P =
.003). Both coronary ostia were more frequently visualized in group 1 (18 vs. 2 cases;
P < .001). ICE derived annulus measurements correlated tightly with preinterventional
TEE readings (n = 20, R = 0.90, P < .001). TEE underestimated intraprocedural
pressure gradients in comparison to preinterventional measurements (mean difference:
-10.2 ± 11.1 mm Hg, n = 11, P = .012), but ICE did not (mean difference: -0.3 ± 14.1
mm Hg, n = 25, P = .913). ICE and TEE detected newly grown thrombi (2 vs. 1 case).
Conclusion: ICE being compatible with sedation and local anesthesia can be
considered an alternative guiding tool to TEE. It also seems to match the required
workflow during TAVR better than TEE.
TCT-133
Management of Paravalvular Leaks During & After Transcatheter Valve
Replacement
Claudia A Martinez, Vikas Singh, Brian O’Neill, Alan W Heldman, William W
O’Neill
University of Miami, Miller School of Medicine, Miami, FL
Background: In an era of Transcatheter Aortic Valve Replacement (TAVR), aortic
paravalvular leak (PVL) represents a regurgitant space in between the frame of the
valve and the native tissues. Best practice to manage this important disorder is not yet
known.
Methods: Patients that underwent TAVR with Edwards SAPIEN (ES) aortic valve at
our center between April 2008 & May 2011 were identified retrospectively. The study
population consisted of those with either acute severe PVL requiring additional
maneuvers during the index TAVR procedure or symptomatic PVL requiring later
treatment by transcatheter closure. Transesophageal echocardiography (TEE) was used
to diagnose and plan the procedures. Procedural success was defined by a reduction in
the degree of PVL assessed by TEE.
Results: A total of 95 patients with TAVR were identified of which 21 required
intervention for PVL (13/21 had a 23 mm and 8/21 had a 26 mm ES valve). There was
no difference in the risk of developing PVR between the two valve sizes (22% for
each). 16/21 had severe PVL immediately after TAVR and underwent repeat balloon
post-dilatation of the implant during the index procedure, 5/21 patients underwent
“Valve in Valve” implantation of a second valve during the index procedure, 3/21
patients had PVL with refractory heart failure that required transcatheter closure
attempts 43 ±10 days after TAVR using vascular plugs, ventricular septal occluders or
coils. The most frequent location of PVL was posterior (non-coronary cusp> left cusp>
right cusp). A total of 26 procedures were performed: one patient required four and
two required two procedures each. The approach was retrograde in 17/26 (65%),
antegrade transeptal in 1/26 (3.8%) and antegrade transapical in 8/26 (30.7%). The
procedure was successful in 23/26 (88.5%) with a 30-day mortality of 1/21 (4.7%).
Peri-procedural complications occurred in 5/21 (23%), including acute kidney injury
requiring hemodialysis in 2, temporary complete heart block requiring pacing in 2, and
ischemic stroke in 1 patient.
Conclusion: PVL is a challenging complication after TAVR, when clinically significant
a variety of treatments can be applied, but dedicated tools may be required for optimal
management.
TCT-134
Immediate Results and Mid-term Follow-Up of Transcatheter Closure of
Paravalvular Leaks with Amplatzer Vascular Plug III Device
Manuel A Paulo, Jaime Dutary, Rosana Hernandez Antolin, Carlos Almeria, Ana
Cuadrado, Carlos Macaya, Eulogio Garcia
Interventional Cardiology, University Hospital San Carlos, Madrid, Spain
Background: Transcatheter closure of paravalvular leaks (PVL) is a recent therapeutic
option for high-risk surgical patients (P). The Amplatzer Vascular Plug III (AVP III)
device has shown safety for this purpose with good immediate results, but its mid and
long term efficacy need to be determined. The purpose of this study is to describe the
immediate results of a series of cases using the AVP III and clinical follow up.
Methods: Methods. Prospective, observational and single centre study of consecutive
P, between January 2008 and May 2011, with transcatheter PVL closure using the AVP
III device, immediate results and clinical follow-up.
Results: A total of 56 P were included (46 with mitral PVL, 7 P with aortic PVL and
3 P with mitral plus aortic PVL). Mean age was 68 ± 11 years. Mean logistic
EuroSCORE was 20±14. Eighty-four percent were in NYHA class III or IV. Clinical
indication was congestive heart failure plus severe haemolytic anemia in 71%. All
procedures except in 1 P (brachial access) were performed through femoral access.
Procedure was successful in 44 (93%) P, although in 29% more than one attempt was
required. There was only one major vascular complication and 1 P required new surgery
due to interference of the device with mitral prosthesis. At a mean follow-up (median
= 364 days, ICR = 125 – 617), majority of P (67%) were in functional class II or I.
Haemoglobin values were also increased at follow up (9.4 ± 1.6 pre vs. 10.4± 1.8 post
p=0.01), and free survival from cardiac death at 30 days, 6 months and 1 year was
96%, 84% and 80% respectively.
Conclusion: PVLs transcatheter closure with AVP III is safe with a high rate of
procedural success, following by acceptable clinical improvement at midterm follow-
up.
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